Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.
Lawrence NJ, Martin A, Davis ID, Troon S, Sengupta S, Hovey E, Coskinas X, Kaplan R, Smith B, Ritchie A, Meade A, Eisen T, Blinman P, Stockler MR. Lawrence NJ, et al. Among authors: eisen t. Kidney Cancer. 2018 Aug 1;2(2):123-131. doi: 10.3233/KCA-180038. Kidney Cancer. 2018. PMID: 30740581 Free PMC article.
Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer.
Henrion M, Frampton M, Scelo G, Purdue M, Ye Y, Broderick P, Ritchie A, Kaplan R, Meade A, McKay J, Johansson M, Lathrop M, Larkin J, Rothman N, Wang Z, Chow WH, Stevens VL, Ryan Diver W, Gapstur SM, Albanes D, Virtamo J, Wu X, Brennan P, Chanock S, Eisen T, Houlston RS. Henrion M, et al. Among authors: eisen t. Hum Mol Genet. 2013 Feb 15;22(4):825-31. doi: 10.1093/hmg/dds489. Epub 2012 Nov 25. Hum Mol Genet. 2013. PMID: 23184150 Free PMC article.
Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer.
Henrion MY, Purdue MP, Scelo G, Broderick P, Frampton M, Ritchie A, Meade A, Li P, McKay J, Johansson M, Lathrop M, Larkin J, Rothman N, Wang Z, Chow WH, Stevens VL, Diver WR, Albanes D, Virtamo J, Brennan P, Eisen T, Chanock S, Houlston RS. Henrion MY, et al. Among authors: eisen t. PLoS One. 2015 Mar 31;10(3):e0122589. doi: 10.1371/journal.pone.0122589. eCollection 2015. PLoS One. 2015. PMID: 25826619 Free PMC article.
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Bex A, Joniau S, Hancock B, Hermann GG, Bellmunt J, Hodgkinson E, Stewart GD, Barber J, Brown J, McMenemin R, Nathan P, Pickering LM, Parmar MKB, Meade A. Eisen T, et al. J Clin Oncol. 2020 Dec 1;38(34):4064-4075. doi: 10.1200/JCO.20.01800. Epub 2020 Oct 14. J Clin Oncol. 2020. PMID: 33052759 Free PMC article. Clinical Trial.
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.
Meade A, Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Harrison DJ, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Larkin J, Parmar MKB. Meade A, et al. Among authors: eisen t. Contemp Clin Trials. 2021 Sep;108:106481. doi: 10.1016/j.cct.2021.106481. Epub 2021 Sep 16. Contemp Clin Trials. 2021. PMID: 34538401 Free PMC article. Clinical Trial.
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Harrison D, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Parmar MKB, Larkin J, Meade A. Oza B, et al. Among authors: eisen t. Contemp Clin Trials. 2021 Sep;108:106482. doi: 10.1016/j.cct.2021.106482. Epub 2021 Sep 16. Contemp Clin Trials. 2021. PMID: 34538402 Free PMC article. Clinical Trial.
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Oza B, Eisen T, Frangou E, Stewart GD, Bex A, Ritchie AWS, Kaplan R, Smith B, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Joniau S, Hancock B, Hermann GG, Bellmunt J, Parmar MKB, Royston P, Meade A. Oza B, et al. Among authors: eisen t. J Clin Oncol. 2022 Jun 1;40(16):1772-1782. doi: 10.1200/JCO.21.01090. Epub 2022 Feb 25. J Clin Oncol. 2022. PMID: 35213214 Free PMC article. Clinical Trial.
Reply to U. Capitanio et al.
Oza B, Eisen T, Stewart GD, Bex A, Royston P, Meade A; authors on the SORCE TMG. Oza B, et al. Among authors: eisen t. J Clin Oncol. 2023 Jan 20;41(3):704-706. doi: 10.1200/JCO.22.01124. Epub 2022 Sep 27. J Clin Oncol. 2023. PMID: 36166721 No abstract available.
247 results